Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

Decongestants and Hypertension: Dangerous Together

MAR 02, 2017 | CLARENCE D. MOORE, PHARMD, BCPS
Nearly 33% of adults in the United States have the typically symptomless disease known as hypertension.1 When healthcare providers treat these individuals, caution should be exercised, as several medications are contraindicated. For example, because decongestants—which are frequently used to manage nasal congestion—can increase blood pressure (BP), their use is a concern in patients with hypertension.
 
Nasal congestion is a typical symptom of the common cold, occurring when nasal and adjacent tissues and blood vessels become swollen with excess fluid.2 This symptom has been described as the most bothersome by adults with allergies.2,3 Individuals with nasal conges­tion are encouraged to drink plenty of fluids to thin mu­cus and promote nasal drainage, in addition to getting plenty of rest and limiting activities.4 OTC medications are often used to manage symptoms; however, they do not shorten the duration of illness and only offer tem­porary relief.
 
Individuals with hypertension should be made aware that decongestants can elevate their BP. Various medical guidelines characterize hypertension in adults as a sys­tolic BP of 140 mm Hg or higher or a diastolic BP of 90 mm Hg or higher.5 Hypertension is treated by using var­ious methods to decrease BP to a predetermined target. The American Heart Association warns all individuals with hypertension, including those being treated for it, to read the labels on all OTC medications prior to use.6  

DECONGESTANTS 

Nasal decongestants are vasoconstrictors that belong to the pharmacologic class “sympathomimetic amines.” They exert their primary action by activating alpha-ad­renergic receptors on blood vessels of the nasal mucosa. This results in vasoconstriction, which decreases blood flow through the nasal mucosa and shrinks tissue.7 De­congestants are available in multiple formulations with varying degrees of systemic effects, including potential elevation of BP.
 
Oral Decongestants
The decongestants pseudoephedrine and phenylephrine may offer mild relief from nasal congestion associated with the common cold.8 These medications are admin­istered alone or in combination with antihistamines, which minimize other symptoms associated with the common cold.
 
Pseudoephedrine is a common ingredient in more than 135 medications and has proved effective in treat­ing nasal congestion. Although a 2005 meta-analysis that showed the drug significantly increased systolic BP (0.99 mm Hg) and heart rate (2.83 beats/min), the results re­vealed no effect on diastolic BP. Higher BP increases were associated with higher doses and immediate-release formulations of pseudoephedrine.9 Studies comparing phenylephrine with placebo showed no significant im­provement in measures of nasal congestion. There is a lack of data on phenylephrine’s effect on BP.
 
Phenylephrine and pseudoephedrine have been de­scribed as safe and effective for treating nasal conges­tion.9 However, as a result of the Combat Methamphet­amine Epidemic Act of 2005, pseudoephedrine products are kept behind the pharmacy counter and have certain restrictions regarding their purchase.
 
Topical Decongestants
Naphazoline, oxymetazoline, and phenylephrine are commonly used topical decongestants. Although these agents are expected to promote local activity, the FDA requires their instructions to contain a warning for in­dividuals with high BP; however, the data on the con­nection between their use and hypertension are sparse. Unlike other topical decongestants, propylhexedrine is a topical OTC decongestant that is not required to carry a warning against unsupervised use in patients with hy­pertension.10 The use of topical nasal decongestants for more than 5 days is associated with the development of rhinitis medicamentosa, also known as “rebound rhini­tis,” which can lead to user dependency.11
 


Want more information on this topic and the opportunity to ask questions of an expert? Register for a live, ACPE accredited webinar February 28th 8-9 PM EST at this link: https://www.pharmacytimes.org/live-events/1106
FEATURED
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.